For Immediate Release
Chicago, IL October 15, 2021 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: CRISPR Therapeutics AG CRSP, Editas Medicine, Inc. EDIT, Sarepta Therapeutics, Inc. SRPT and Beam Therapeutics Inc. BEAM.
Gene therapy is one of the novel mechanisms of treatment that is attracting several large and small pharma companies. The gene therapies treat a disease by altering or turning off problematic genes and adding genes that help to fight or treat a disease. Scientists have been investigating ways to modify genes or replace faulty genes for the last few decades with a few gene therapies already in the market. Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector.
These therapies provide the flexibility to develop one-time treatment options for genetic or inherited diseases with limited or no approved therapies available. Moreover, gene-editing can directly affect cells the basic building blocks of living things and may help in developing highly effective therapies.
There are already a few FDA-approved gene therapies targeting different difficult indications. In a historic move, the FDA approved the first gene therapy, Novartis Kymriah, for treating acute lymphoblastic leukemia in 2017. This was followed by the FDA approval of two more gene therapies Gileads Yescarta and Roches Luxturna for oncology and eye disorder indications, respectively, in the same year.
The FDA approved two new gene therapies, Bristol-Myers Breyanzi and Abecma for treating different cancer indications, earlier in 2021. The majority of approved gene therapies have shown strong sales growth since their approval.
Given the potential of gene therapies to treat complex diseases, the companies developing candidates using gene therapy that are a mix of large and small firms, are in focus. A successful medicine developed by any of these companies can generate annual revenues of $1 billion or more. Here we discuss four biotech stocks with promising gene therapy candidates in their pipeline.
The company is developing its lead pipeline candidate, CTX001, in collaboration with Vertex Pharmaceuticals in mid-stage studies as a potential treatment for transfusion-dependent beta thalassemia and sickle cell disease. The gene-editing therapy candidate previously demonstrated a consistent and sustained response to treatment in the given patient population in an ongoing phase I/II study.
CRISPR Therapeutics is actively seeking collaborations and leveraging its CRISPR/Cas9 gene-editing platform to make therapies for hemoglobinopathies, cancer, diabetes and other diseases.
The companys lead pipeline candidate is EDIT-101, which employs CRISPR gene editing to treat LCA10 a rare genetic illness that causes blindness. Editas is currently enrolling in the first pediatric cohort of the phase I/II BRILLIANCE study, which is evaluating EDIT-101 for LCA10. Editas is also pursuing the development of CRISPR candidates for eye diseases other than LCA10 including Usher Syndrome type 2A and recurrent ocular Herpes Simplex Virus type 1.
It is also designing novel medicines for non-malignant hematologic diseases, such as SCD and beta-thalassemia.
Sareptas lead gene therapy candidate is SRP-9001, an AAV-mediated micro-dystrophin gene therapy. The company initiated a pivotal clinical study earlier this year to evaluate it as a one-time treatment for Duchenne muscular dystrophy patients. The promising candidate has also led Roche to sign a collaboration deal with Sarepta.
The company plans to seek FDAs approval to start a pivotal study on its other gene therapy candidate, SRP-9003, in 2021 to evaluate it in patients with Limb-girdle muscular dystrophy (LGMD) type 2E. The company has several other pre-clinical and clinical-stage gene therapy candidates targeting additional indications like Rett Syndrome, cardiomyopathy, Emery-Dreifuss muscular dystrophy type 1, and multiple sclerosis.
The company has two pre-clinical gene editing candidates, BEAM-101 and BEAM-102, in its pipeline that are being developed as potential treatments for SCD. The company plans to file an investigational new drug application to the FDA seeking approval to start a clinical study on BEAM-101 in the second half of 2021.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein andis subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportBeam Therapeutics Inc. (BEAM) : Free Stock Analysis ReportSarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis ReportEditas Medicine, Inc. (EDIT) : Free Stock Analysis ReportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 21st, 2021
- Immunosuppressants linked to severe reactions in people with common genetic profile - Stanford Medical Center Report - November 21st, 2021
- A video that originated on InfoWars is filled with falsehoods about COVID-19 vaccines - PolitiFact - November 21st, 2021
- Gene signature may give an upper hand in metastatic breast cancer - Baylor College of Medicine News - November 21st, 2021
- Lung cancer management in the era of precision medicine - Express Healthcare - November 21st, 2021
- Powerful gene-based testing by integrating long-range chromatin interactions and knockoff genotypes - pnas.org - November 21st, 2021
- Stoke Therapeutics Announces Presentations from the Company's Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting - Business... - November 21st, 2021
- European Commission approves Roche's Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer |... - November 21st, 2021
- Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring - pnas.org - November 21st, 2021
- Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With... - November 21st, 2021
- Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled... - November 21st, 2021
- Gene Therapy and Genetic Engineering - MU School of Medicine - November 17th, 2021
- Gene editing: Great for medicine but ethical issues arise - November 17th, 2021
- Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders - FierceBiotech - November 17th, 2021
- gene therapy | Description, Uses, Examples, & Safety ... - November 17th, 2021
- Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development - Yahoo Finance - November 17th, 2021
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes -... - November 17th, 2021
- 8 medical advances you may have missed during COVID-19 - AAMC - November 17th, 2021
- PNAS Papers on Woodrat Microbiome, Maternal Cannabis Use, Gene-Based Testing - GenomeWeb - November 17th, 2021
- Single Cell Multiomic Atlas of the Human Retina: An Integrative Analysis - Genetic Engineering & Biotechnology News - November 17th, 2021
- Map of Mouse Iris Offers New Look at the Eye - Howard Hughes Medical Institute - November 17th, 2021
- Is every gene associated with cancer? - Medical News Today - November 15th, 2021
- Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy - BioPharma Dive - November 15th, 2021
- A mammoth solution - Harvard Office of Technology Development - November 15th, 2021
- Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Franon PhD as Chief... - November 15th, 2021
- Cell and Gene Therapy Catapult and Deep Science Ventures collaborate to overcome barriers in ATMPs - BioPharma-Reporter.com - November 15th, 2021
- Regenerative Medicine Market to reach US$ 25,959.5 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 15th, 2021
- Dr Pengyi Yang wins National Stem Cell Foundation Metcalf Prize - News - The University of Sydney - November 15th, 2021
- Researchers make strides identifying genetic causes of rare neurodevelopmental disorders in the Turkish and worldwide populations - Baylor College of... - November 15th, 2021
- Saving the world with synthetic biology - Scope - Scope - November 15th, 2021
- GenSight Biologics to Present New Clinical Data of LUMEVOQ and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting - Business... - November 15th, 2021
- Gene Therapy ADVM-022 Provides Mixed Efficacy, Safety in Treating DME - MD Magazine - November 15th, 2021
- Role of gene associated with Alzheimer's disease in brain's immune cells investigated by scientists - Devdiscourse - November 15th, 2021
- Attitudes among parents of persons with autism spectrum disorder towards information about genetic risk and future health | European Journal of Human... - November 15th, 2021
- Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED - PRNewswire - November 15th, 2021
- Arizona researchers have a Valley fever vaccine for dogs and that's good news for humans - KJZZ - November 15th, 2021
- Study revealed the function of mysterious structure found on neurons - Tech Explorist - November 15th, 2021
- New Research Helps Explain the Genetic Basis of Why We Look the Way We Do - UC San Diego Health - November 15th, 2021
- Gene Therapy Shows Early Promise as Angelman Syndrome Treatment | Newsroom - UNC Health and UNC School of Medicine - October 26th, 2021
- Report by Mott Center researchers named NIEHS Extramural Paper of the Month - The South End - October 26th, 2021
- Clinical Data from Editas Medicines Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene... - October 26th, 2021
- Delic Partners With GT Research for Genetic Analysis of Cannabis, Psychedelic Mushrooms - GenomeWeb - October 26th, 2021
- Alcyone Therapeutics Strengthens Executive Team with New Senior Leadership Appointments - WABI - October 26th, 2021
- The Genomic Revolution: Why Investors Are Paying Attention - Visual Capitalist - October 26th, 2021
- Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T in Advanced ROR1+ Hematological and Solid Tumors - WAGM - October 26th, 2021
- 5 Trends Shaping the Future of eCommerce - Visual Capitalist - October 26th, 2021
- Anatomy texts should show sex as a spectrum to include intersex people - The Conversation AU - October 26th, 2021
- Early Results of Gene Therapy for Angelman Syndrome Look Promising - AJMC.com Managed Markets Network - October 24th, 2021
- Ten Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune Disease - HealthDay News - October 24th, 2021
- Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit - Yahoo Finance - October 24th, 2021
- Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery... - October 24th, 2021
- ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit - WCAX - October 24th, 2021
- Lovelace Biomedical Presents a New Webinar on Rare Diseases and Gene Therapy Preclinical Research - PRNewswire - October 24th, 2021
- Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there? - FiercePharma - October 24th, 2021
- Senti Bio CEO Appointed to The Alliance for Regenerative Medicine 2022 Board of Directors - StreetInsider.com - October 24th, 2021
- ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs - MedCity News - October 24th, 2021
- From cancer to Crohn, Israel pushes precision medicine to the next level - The Jerusalem Post - October 24th, 2021
- Tulane scientists unravel 50-year-old medical mystery behind toddlers' deaths from RSV vaccine - Tulane News - October 24th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 24th, 2021
- Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy - Cystic Fibrosis News Today - October 24th, 2021
- LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using... - October 24th, 2021
- Global Pharmaceutical Contract Development and Manufacturing Markets, 2021-2026 - Increasing Demand for Biological & Cell and Gene Therapies /... - October 24th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - The Highland County Press - October 24th, 2021
- Hunterian Medicine Licenses Inscriptas MAD7 Nuclease to Advance Gene Editing Research and Development - Yahoo Finance - October 17th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 17th, 2021
- 4 Biotechs to Watch Amid Rising Prominence of Gene Therapies - Yahoo Finance - October 17th, 2021
- Could an Old Drug Be a New Alzheimers Treatment? - AARP - October 17th, 2021
- 5 Slides: Gene therapy and the promise for rare disease - State of Reform - State of Reform - October 17th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 17th, 2021
- Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress - StreetInsider.com - October 17th, 2021
- Genetic screening test leads to discovery of a family trait - Sanford Health News - October 17th, 2021
- Filling the gaps: connecting genes to diseases through proteins - EurekAlert - October 17th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - GlobeNewswire - October 17th, 2021
- Polygenic screening of embryos is here, but is it ethical? - The Guardian - October 17th, 2021
- Wolter Earns Young Investigator Award | Newsroom - UNC Health and UNC School of Medicine - October 17th, 2021
- Patient Care on the Precipice of Transformation at Penn Medicine's New Pavilion - pennmedicine.org - October 17th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 11th, 2021
- CRISPR is revolutionizing medicine its origin story is pretty incredible, too - Freethink - October 11th, 2021
- Longevity Foundation to Fund Geroscience Research with 860M - Labiotech.eu - October 11th, 2021
- Explained | The 2021 Nobel Prize in Physiology or Medicine - The Hindu - October 11th, 2021